Get the Daily Brief
Latest Biotech News
Boehringer, Bayer neck-and-neck in front-line HER2‑mutant lung
Boehringer Ingelheim and Bayer presented front-line data for targeted therapies in HER2‑mutant lung cancer at ESMO, with each company reporting tumor shrinkage and clinical activity in...
First‑in‑class YAP‑TEAD inhibitor shows early mesothelioma activity
Investigators at MD Anderson reported early clinical activity for VT3989, a first‑in‑class YAP–TEAD inhibitor, in heavily pretreated patients with refractory mesothelioma and other solid tumors....
BioCryst shells out $700M for Astria to chase HAE market
BioCryst agreed to acquire Astria Therapeutics for $700 million, adding navenibart—a Phase 3 injectable antibody for hereditary angioedema—to its pipeline. Management framed the deal as a bid to...
Lilly Ventures backs NewLimit in $45M anti‑aging raise
NewLimit closed a $45 million financing round that included investment from Lilly Ventures and other new backers, advancing the company’s anti‑aging pipeline. The round positions NewLimit to...
mRNA COVID shots enhance checkpoint inhibitor outcomes — MD Anderson data
Researchers from MD Anderson Cancer Center presented retrospective analyses at ESMO showing cancer patients who received an mRNA COVID‑19 vaccine within 100 days of starting immune checkpoint...
BioCryst buys Astria for $700M — HAE portfolio jumps
BioCryst Pharmaceuticals agreed to acquire Astria Therapeutics for $700 million, adding navenibart — a Phase 3 injectable antibody for hereditary angioedema (HAE) — to its pipeline. The deal...
Gene-editing stocks brace for Q3 — Intellia under the microscope
Investors in gene-editing and genetic-medicine companies are positioning ahead of third-quarter earnings and upcoming clinical readouts, with Intellia Therapeutics taking center stage after...
ADCs climbing the ladder... Enhertu and next-gen agents push into earlier disease
Data presented at ESMO show antibody-drug conjugates (ADCs) moving into earlier-stage breast cancer, with Enhertu demonstrating benefits when used pre‑operatively and next-generation ADCs showing...
Datroway vs Trodelvy — TNBC first‑line fight intensifies
Two competing antibody-drug conjugates—AstraZeneca/Daiichi Sankyo’s Datroway and Gilead’s Trodelvy—posted Phase 3 results at ESMO that both improved outcomes in first‑line metastatic...
Roche’s SERD shows benefit in non‑mutant breast cancer — trial could redraw market
Roche reported that its oral selective estrogen receptor degrader (SERD), giredestrant, demonstrated efficacy in patients without ESR1 mutations—marking the first SERD to show benefit in that...
Tubulis posts 59% response — TUB‑040 validates platform
Tubulis disclosed early clinical data showing a 59% overall response rate for its NaPi2b‑targeting ADC TUB‑040 across multiple dose cohorts in platinum‑resistant ovarian cancer and advanced...
EMBL unveils SDR‑seq: a tool to read hidden DNA regulatory code
EMBL researchers introduced SDR‑seq, a single‑cell method that sequences DNA and RNA from the same cell and exposes non‑coding regulatory regions where most disease‑associated variants lie. The...
mRNA Covid shots boost immunotherapy responses — ESMO and retrospective studies
Multiple teams reported that mRNA Covid‑19 vaccination given near the time of immune checkpoint inhibitor therapy correlated with improved outcomes in advanced cancer patients. MD Anderson...
Syngene builds peptide lab, ramps automation — CRDMO scale‑up
India’s Syngene International completed site upgrades to add a dedicated peptide laboratory in Bengaluru and introduced advanced automation across DMPK and direct‑to‑biology (D2B) workflows. The...
India court allows generic Evrysdi — Roche faces pricing blow
India’s Supreme Court dismissed Roche’s petition and allowed Natco Pharma to sell a lower‑cost generic version of Evrysdi (risdiplam) in India, a decision described in coverage as weighing public...
Enhertu pushes earlier — Phase 3 signals curative potential
AstraZeneca and Daiichi Sankyo presented Phase 3 data at ESMO showing Enhertu improves outcomes when used earlier in breast cancer treatment. The companies reported results indicating meaningful...
Datroway vs Trodelvy: Head‑to‑head ESMO readouts sharpen choice
Two antibody‑drug conjugates—AstraZeneca/Daiichi Sankyo’s Datroway and Gilead’s Trodelvy—delivered competing Phase 3 results at ESMO that both showed benefits versus chemotherapy in first‑line...
Padcev–Keytruda combo extends survival — Phase 3 bladder data
New Phase 3 data presented at ESMO show that the Padcev (enfortumab vedotin) plus Keytruda (pembrolizumab) combination extends overall survival in locally advanced or metastatic bladder cancer....
Grail’s Galleri improves accuracy — PATHFINDER 2 readout alters filing narrative
Grail published PATHFINDER 2 results showing improved positive predictive value (PPV) and a sensitivity of 40.4% for its Galleri multi‑cancer screening test in nearly 36,000 adults over age 50....
BioNTech halts late‑stage melanoma vaccine
BioNTech announced it will not advance a cancer vaccine program in late‑stage melanoma, according to reporting from Endpoints News at ESMO. The company said it remains undecided about studying the...